vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Lightspeed Commerce Inc. (LSPD). Click either name above to swap in a different company.
Lightspeed Commerce Inc. is the larger business by last-quarter revenue ($823.4M vs $722.5M, roughly 1.1× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs -11.1%, a 21.9% gap on every dollar of revenue. Over the past eight quarters, Lightspeed Commerce Inc.'s revenue compounded faster (89.1% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Lightspeed Commerce is a point-of-sale and e-commerce software provider based in Montreal, Quebec, Canada. It was founded in 2005 by Dax da Silva, who was its CEO until February 2022. It has offices in Montreal, New York, Ottawa, Toronto, London, Belfast, Amsterdam, Berlin, Geneva, Ghent, Melbourne, Ulyanovsk, Yerevan and Tbilisi. It offers its services to retail, restaurant, and hospitality businesses.
AMRX vs LSPD — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $823.4M |
| Net Profit | $78.0M | $-91.3M |
| Gross Margin | 44.3% | 41.1% |
| Operating Margin | — | -14.1% |
| Net Margin | 10.8% | -11.1% |
| Revenue YoY | 3.9% | — |
| Net Profit YoY | 217.0% | — |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $823.4M | ||
| Q3 25 | $784.5M | $543.3M | ||
| Q2 25 | $724.5M | $266.1M | ||
| Q1 25 | $695.4M | $253.4M | ||
| Q4 24 | $730.5M | $679.1M | ||
| Q3 24 | $702.5M | $439.4M | ||
| Q2 24 | $701.8M | $209.1M |
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $-91.3M | ||
| Q3 25 | $2.4M | $-64.7M | ||
| Q2 25 | $22.4M | $-35.0M | ||
| Q1 25 | $12.2M | $-575.9M | ||
| Q4 24 | $-31.1M | $-131.4M | ||
| Q3 24 | $-156.0K | $-91.2M | ||
| Q2 24 | $6.0M | $-48.7M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 41.1% | ||
| Q3 25 | 34.9% | 41.0% | ||
| Q2 25 | 39.5% | 40.7% | ||
| Q1 25 | 36.8% | 44.1% | ||
| Q4 24 | 36.0% | 42.1% | ||
| Q3 24 | 38.4% | 41.9% | ||
| Q2 24 | 35.6% | 42.0% |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | -14.1% | ||
| Q3 25 | 9.0% | -15.1% | ||
| Q2 25 | 15.4% | -16.6% | ||
| Q1 25 | 14.4% | -228.9% | ||
| Q4 24 | 10.4% | -23.8% | ||
| Q3 24 | 12.6% | -25.1% | ||
| Q2 24 | 13.6% | -27.9% |
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | -11.1% | ||
| Q3 25 | 0.3% | -11.9% | ||
| Q2 25 | 3.1% | -13.2% | ||
| Q1 25 | 1.8% | -227.3% | ||
| Q4 24 | -4.3% | -19.4% | ||
| Q3 24 | -0.0% | -20.8% | ||
| Q2 24 | 0.9% | -23.3% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | $-0.01 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
LSPD
Segment breakdown not available.
